featured
Patisiran for Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Long-Term Safety and Efficacy of Patisiran for Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy: 12-Month Results of an Open-Label Extension Study
Lancet Neurol 2021 Jan 01;20(1)49-59, D Adams, M Polydefkis, A González-Duarte, J Wixner, AV Kristen, HH Schmidt, JL Berk, IA Losada López, A Dispenzieri, D Quan, IM Conceição, MS Slama, JD Gillmore, T Kyriakides, S Ajroud-Driss, M Waddington-Cruz, MM Mezei, V Planté-Bordeneuve, S Attarian, E Mauricio, TH Brannagan, M Ueda, E Aldinc, JJ Wang, MT White, J Vest, E Berber, MT Sweetser, T CoelhoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.